Cargando…

Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life

PURPOSE: To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the patient perspective, and capture the “patient v...

Descripción completa

Detalles Bibliográficos
Autores principales: Epstein, Robert S, Basu Roy, Upal K, Aapro, Matti, Salimi, Tehseen, Moran, Donald, Krenitsky, JoAnn, Leone-Perkins, Megan L, Girman, Cynthia, Schlusser, Courtney, Crawford, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920579/
https://www.ncbi.nlm.nih.gov/pubmed/33658769
http://dx.doi.org/10.2147/PPA.S292462
_version_ 1783658304868712448
author Epstein, Robert S
Basu Roy, Upal K
Aapro, Matti
Salimi, Tehseen
Moran, Donald
Krenitsky, JoAnn
Leone-Perkins, Megan L
Girman, Cynthia
Schlusser, Courtney
Crawford, Jeffrey
author_facet Epstein, Robert S
Basu Roy, Upal K
Aapro, Matti
Salimi, Tehseen
Moran, Donald
Krenitsky, JoAnn
Leone-Perkins, Megan L
Girman, Cynthia
Schlusser, Courtney
Crawford, Jeffrey
author_sort Epstein, Robert S
collection PubMed
description PURPOSE: To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the patient perspective, and capture the “patient voice” describing how CIM impacts their daily lives. PARTICIPANTS AND METHODS: Online survey of participants with breast, lung, or colorectal cancer who had received chemotherapy within the past 12 months and experienced ≥1 episode of CIM in the past year. Participants were asked to answer close-ended questions and provide qualitative responses to: “In your own words, please describe how side effects from myelosuppression have impacted your life.” RESULTS: Among 301 survey participants, fatigue was the most frequently reported side effect of chemotherapy; 55% of participants rated fatigue as highly bothersome (9 or 10 on a 1–10 scale of “bothersomeness”). Participants rated symptoms associated with CIM, including fatigue, weakened immune system (infections), bleeding and/or bruising, and shortness of breath, as being as bothersome as other side effects of chemotherapy, including alopecia, neuropathy, and nausea/vomiting. Overall, 24–43% of participants thought that CIM and its symptoms had a negative impact on their daily lives, including their ability to complete tasks at home and work, and to socialize. Qualitative responses supported these findings; participants highlighted that CIM-related symptoms, particularly fatigue and fear of infections, affected their ability to be physically active, complete work, or continue meaningful relationships with friends and family. CONCLUSION: Participants described a real-world impact of CIM that often isolates them from family and friends, and means that they are unable to work or perform tasks of daily living. Using measures that help patients to recognize and communicate the signs and symptoms of CIM might increase the likelihood of maintaining daily lives as close to normal as possible, during and after chemotherapy treatment.
format Online
Article
Text
id pubmed-7920579
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79205792021-03-02 Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life Epstein, Robert S Basu Roy, Upal K Aapro, Matti Salimi, Tehseen Moran, Donald Krenitsky, JoAnn Leone-Perkins, Megan L Girman, Cynthia Schlusser, Courtney Crawford, Jeffrey Patient Prefer Adherence Original Research PURPOSE: To evaluate which side effects of chemotherapy are considered most burdensome by patients with cancer, identify which health care professionals pay most attention to symptoms associated with chemotherapy-induced myelosuppression (CIM) from the patient perspective, and capture the “patient voice” describing how CIM impacts their daily lives. PARTICIPANTS AND METHODS: Online survey of participants with breast, lung, or colorectal cancer who had received chemotherapy within the past 12 months and experienced ≥1 episode of CIM in the past year. Participants were asked to answer close-ended questions and provide qualitative responses to: “In your own words, please describe how side effects from myelosuppression have impacted your life.” RESULTS: Among 301 survey participants, fatigue was the most frequently reported side effect of chemotherapy; 55% of participants rated fatigue as highly bothersome (9 or 10 on a 1–10 scale of “bothersomeness”). Participants rated symptoms associated with CIM, including fatigue, weakened immune system (infections), bleeding and/or bruising, and shortness of breath, as being as bothersome as other side effects of chemotherapy, including alopecia, neuropathy, and nausea/vomiting. Overall, 24–43% of participants thought that CIM and its symptoms had a negative impact on their daily lives, including their ability to complete tasks at home and work, and to socialize. Qualitative responses supported these findings; participants highlighted that CIM-related symptoms, particularly fatigue and fear of infections, affected their ability to be physically active, complete work, or continue meaningful relationships with friends and family. CONCLUSION: Participants described a real-world impact of CIM that often isolates them from family and friends, and means that they are unable to work or perform tasks of daily living. Using measures that help patients to recognize and communicate the signs and symptoms of CIM might increase the likelihood of maintaining daily lives as close to normal as possible, during and after chemotherapy treatment. Dove 2021-02-25 /pmc/articles/PMC7920579/ /pubmed/33658769 http://dx.doi.org/10.2147/PPA.S292462 Text en © 2021 Epstein et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Epstein, Robert S
Basu Roy, Upal K
Aapro, Matti
Salimi, Tehseen
Moran, Donald
Krenitsky, JoAnn
Leone-Perkins, Megan L
Girman, Cynthia
Schlusser, Courtney
Crawford, Jeffrey
Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
title Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
title_full Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
title_fullStr Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
title_full_unstemmed Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
title_short Cancer Patients’ Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life
title_sort cancer patients’ perspectives and experiences of chemotherapy-induced myelosuppression and its impact on daily life
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920579/
https://www.ncbi.nlm.nih.gov/pubmed/33658769
http://dx.doi.org/10.2147/PPA.S292462
work_keys_str_mv AT epsteinroberts cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT basuroyupalk cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT aapromatti cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT salimitehseen cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT morandonald cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT krenitskyjoann cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT leoneperkinsmeganl cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT girmancynthia cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT schlussercourtney cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife
AT crawfordjeffrey cancerpatientsperspectivesandexperiencesofchemotherapyinducedmyelosuppressionanditsimpactondailylife